Retrospective study of the prognostic factors of remission induction for single-agent chemotherapy with cisplatin in advanced epithelial ovarian cancer

A retrospective study to explore the prognostic factor was conducted in 39 patients with advanced epithelial ovarian cancer, FIGO stage III-IV, who un derwent single-agent adjuvant chemotherapy with cisplatin following primary debulking surgery. The survival rate following the adjuvant chemotherapy w as 50.9% after 3 years and 44.7% after 5 years, with a median survival time of 40.4 months. The actual dose intensity of the cisplatin ranged from 14. 38 to 46.30 mg/m(2)/week, and the total dose/m(2) was 143.79 to 645.83 mg/m (2). Under these therapeutic conditions, the actual dose intensity was foun d to correlate with survival time (p<0.05), but there was no correlation be tween the total dose/m(2) and survival time.